Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis
Sang-Hyon Kim, So-Yeon Lee, Ji-Min Kim, Chang-Nam Son
Korean J Intern Med. 2020;35(4):998-1003. Published online 2019 Apr 8 DOI: https://doi.org/10.3904/kjim.2018.423
Citations to this article as recorded by 
Febuxostat dose requirement according to renal function in patients who achieve target serum urate levels: A retrospective cohort study
Young-Eun Kim, Soo Min Ahn, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo, Seokchan Hong
Joint Bone Spine.2024; 91(2): 105668. CrossRef
Treatment of Gout in Patients with CrCl ≤30 mL/min and/or on Hemodialysis: A Review
Fares Saliba, Omar Mourad, Jonathan Mina, Fadi Haddadin, Laurence Aoun, Shaza Almardini, Saif Abu-baker, Koushik Sangaraju, Gaetano Di Pietro, Daniel Gaballa, Suzanne El-sayegh
Rheumato.2024; 4(1): 49. CrossRef
A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Sakura Iida, Hisayuki Katsuyama
Cells.2024; 13(5): 450. CrossRef
The Hong Kong Society of Rheumatology consensus recommendations for the management of gout
Ronald ML Yip, Tommy T Cheung, Ho So, Julia PS Chan, Carmen TK Ho, Helen HL Tsang, Carrel KL Yu, Priscilla CH Wong
Clinical Rheumatology.2023; 42(8): 2013. CrossRef
Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications
Hans-Joachim Anders, Qiubo Li, Stefanie Steiger
Clinical Kidney Journal.2023; 16(6): 928. CrossRef
Principles of urate-lowering therapy: eight steps to success
O. V. Zhelyabina, M. S. Eliseev, A. M. Lila
Modern Rheumatology Journal.2023; 17(3): 104. CrossRef
Current state and prospects of gout treatment in Korea
Eun Hye Park, Sang Tae Choi, Jung Soo Song
The Korean Journal of Internal Medicine.2022; 37(4): 719. CrossRef
Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4–5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies
Hye-Jin Jeong, Woo Yeong Park, Sang-Hyon Kim, Nicola Dalbeth, Chang-Nam Son
Seminars in Arthritis and Rheumatism.2022; 56: 152073. CrossRef
Febuxostat as an effective drug of choice for urate-lowering therapy for gout (case report)
A. B. Bashkova, I. V. Madyanov
Meditsinskiy sovet = Medical Council.2022; (14): 137. CrossRef
Febuxostat Therapy for Patients with Gout and Stage 2–4 CKD: a Retrospective Study
Peiyu Zhang, Mo Chen, Jundi Wang, Shunjie Hu, Xiaoyong Lu, Huaxiang Wu
Rheumatology and Therapy.2022; 9(5): 1421. CrossRef
ACR management guidelines for the treatment of gout: What’s new and what’s controversial
M. S. Eliseev
Rheumatology Science and Practice.2021; 59(2): 129. CrossRef
Pharmacotherapy for gout
Chang-Nam Son
Journal of the Korean Medical Association.2021; 64(11): 772. CrossRef
Clinical discussion: gout therapy in a comorbid patient
M. S. Eliseev, A. M. Novikova
Meditsinskiy sovet = Medical Council.2020; (11): 154. CrossRef
Commentaries on the updated American College of Rheumatology guidelines for the management of gout. Urate-lowering drugs (Part 1)
M. S. Eliseev
Modern Rheumatology Journal.2020; 14(3): 117. CrossRef
Renal effects of uric acid: hyperuricemia and hypouricemia
Jung Hwan Park, Yong-Il Jo, Jong-Ho Lee
The Korean Journal of Internal Medicine.2020; 35(6): 1291. CrossRef